CTXR
Income statement / Annual
Last year (2025), Citius Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Citius Pharmaceuticals Inc's net income was -$37.43 M.
See Citius Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$214.25 K
|
$209.61 K
|
$194.32 K
|
$179.68 K
|
$164.87 K
|
$152.36 K
|
$893.00
|
$1.75 K
|
$2.63 K
|
$1.34 K
|
| Gross Profit |
-$214.25 K
|
-$209.61 K
|
-$194.32 K
|
-$179.68 K
|
-$164.87 K
|
-$152.36 K
|
-$893.00
|
-$1.75 K
|
-$2.63 K
|
-$1.34 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.16 M
|
$11.91 M
|
$14.82 M
|
$17.66 M
|
$12.24 M
|
$8.81 M
|
$8.60 M
|
$6.56 M
|
$2.94 M
|
$2.93 M
|
| General & Administrative Expenses |
$18.53 M
|
$18.25 M
|
$21.91 M
|
$15.66 M
|
$11.29 M
|
$8.90 M
|
$7.00 M
|
$7.23 M
|
$7.05 M
|
$4.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.53 M
|
$18.25 M
|
$21.91 M
|
$15.66 M
|
$11.29 M
|
$8.90 M
|
$7.00 M
|
$7.23 M
|
$7.05 M
|
$4.52 M
|
| Other Expenses |
$10.62 M
|
$11.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$38.31 M
|
$42.00 M
|
$36.73 M
|
$33.32 M
|
$23.53 M
|
$17.71 M
|
$15.60 M
|
$13.79 M
|
$9.99 M
|
$7.45 M
|
| Cost And Expenses |
$38.53 M
|
$42.00 M
|
$36.73 M
|
$33.32 M
|
$23.53 M
|
$17.71 M
|
$15.60 M
|
$13.79 M
|
$9.99 M
|
$7.45 M
|
| Interest Income |
$110.08 K
|
$758.00 K
|
$1.18 M
|
$251.40 K
|
$261.83 K
|
$68.07 K
|
$52.66 K
|
$0.00
|
$806.00
|
$806.00
|
| Interest Expense |
$267.78 K
|
$0.00
|
$0.00
|
$251.40 K
|
$10.84 K
|
$15.67 K
|
$16.44 K
|
$15.84 K
|
$850.79 K
|
$8.99 K
|
| Depreciation & Amortization |
$214.25 K
|
$209.61 K
|
$194.32 K
|
$179.68 K
|
$164.87 K
|
$152.36 K
|
$893.00
|
$1.75 K
|
$2.63 K
|
$1.34 K
|
| EBITDA |
-$38.20 M |
-$38.64 M |
-$31.77 M |
-$32.88 M |
-$22.88 M |
-$17.38 M |
-$15.54 M |
-$13.79 M |
-$9.98 M |
-$7.45 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$157.70 K
|
$3.15 M
|
$4.77 M
|
$251.40 K
|
$477.46 K
|
$162.60 K
|
$36.22 K
|
$1.25 M
|
-$398.64 K
|
-$846.41 K
|
| Income Before Tax |
-$38.68 M
|
-$38.85 M
|
-$31.97 M
|
-$33.06 M
|
-$23.05 M
|
-$17.55 M
|
-$15.56 M
|
-$12.54 M
|
-$10.38 M
|
-$8.30 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.06 M
|
$576.00 K
|
$576.00 K
|
$576.00 K
|
$0.00
|
$0.00
|
$16.44 K
|
$0.00
|
$0.00
|
$8.99 K
|
| Net Income |
-$37.43 M
|
-$39.14 M
|
-$32.54 M
|
-$33.64 M
|
-$23.13 M
|
-$17.55 M
|
-$15.58 M
|
-$12.54 M
|
-$10.38 M
|
-$8.30 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.38 |
-5.97 |
-5.57 |
-5.76 |
-5.64 |
-0.45 |
-0.77 |
-1.17 |
-1.89 |
-2.29 |
| EPS Diluted |
-3.38 |
-5.97 |
-5.57 |
-5.76 |
-5.64 |
-0.45 |
-0.77 |
-1.17 |
-1.89 |
-2.29 |
| Weighted Average Shares Out |
$11.07 M
|
$11.59 M
|
$9.74 M
|
$9.74 M
|
$7.24 M
|
$2.61 M
|
$1.34 M
|
$715.46 K
|
$365.50 K
|
$241.55 K
|
| Weighted Average Shares Out Diluted |
$11.07 M
|
$11.59 M
|
$10.09 M
|
$9.74 M
|
$7.24 M
|
$2.61 M
|
$1.34 M
|
$715.46 K
|
$365.50 K
|
$241.55 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
